Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03935893 |
TitleAdoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | Phase
Phase 2
|
Date Added 2019-05-02 |
Location
Pennsylvania, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fludarabine + Cyclophosphamide combination, Tumor Infiltrating Lymphocytes (TIL) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03069469 |
TitleStudy of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | Phase
Phase 1, Phase 2
|
Date Added 2017-03-03 |
Location
California, United States
Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canada France Italy Netherlands Poland Spain United Kingdom |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
DCC-3014 |
Tags
MSS/ MMRp
|
| NCT ID NCT04793958 |
TitlePhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | Phase
Phase 3
|
Date Added 2021-03-11 |
Location
Alabama, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Brazil Canada China Colombia Czechia Denmark Finland France Germany Greece Hong Kong Ireland Italy Korea, Republic of Malaysia Mexico Netherlands Poland Portugal Puerto Rico Romania Singapore Spain Taiwan Thailand Ukraine United Kingdom |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT01697371 |
TitleProton Therapy in the Treatment of Liver Metastases | Phase
Not Applicable
|
Date Added 2012-10-02 |
Location
California, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03650348 |
TitlePRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | Phase
Phase 1
|
Date Added 2018-08-28 |
Location
California, United States
Louisiana, United States New York, United States Ohio, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
PRS-343 in Combination with Atezolizumab, Tecentriq |
Tags
MSS/ MMRp
|
| NCT ID NCT02537418 |
TitleDurvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens | Phase
Phase 1
|
Date Added 2015-09-01 |
Location
Canada
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
durvalumab, Tremelimumab, Imfinzi |
Tags
MSS/ MMRp
|
| NCT ID NCT02600949 |
TitlePersonalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | Phase
Phase 1
|
Date Added 2015-11-09 |
Location
Texas, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04110093 |
TitleRegorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer | Phase
Phase 1/Phase 2
|
Date Added 2019-10-01 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Regorafenib and PD-1 inhibitor |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03668431 |
TitleDabrafenib + Trametinib + PDR001 In Colorectal Cancer | Phase
Phase 2
|
Date Added 2018-09-12 |
Location
Massachusetts, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03673787 |
TitleA Trial of Ipatasertib in Combination With Atezolizumab | Phase
Phase 1
|
Date Added 2018-09-17 |
Location
United Kingdom
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Atezolizumab, Ipatasertib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
